China NMPA Approves OptuneŽ for the Treatment of Newly Diagnosed and Recurrent Glioblastoma Optune is finally available in China - 6 years after we had it here in the USA!
In China there are about 45,000 patients diagnosed per year with glioblastoma. That is more than double the number here in the USA.
The press release states: A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1
Brain Tumor Awareness Monthly Webinar Series video posted: Advances in neuro-imaging We just posted the video from our last webinar. Advances in neuro-imaging. This is one of the most important topics we ever covered. It is a new way to look at MRIs that enables you to tell if a treatment is working or not much sooner, and if the thing on your scan is tumor or pseudoprogression.
This is available NOW! Many major medical centers can do it but if your MRI center can not, there are companies that can do it as a service using the MRI files from your scans!
